A clinical approach to treatment resistance in depressed patients: What to do when the usual treatments don’t work well enough?
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Major depressive disorder is a common, recurrent, disabling and costly disorder that is often severe and/or chronic, and for which non-remission on guideline concordant first-line antidepressant treatment is the norm. A sizeable percentage of patients diagnosed with MDD do not achieve full remission after receiving antidepressant treatment. How to understand or approach these 'refractory', 'TRD' or 'difficult to treat' patients need to be revisited. Treatment resistant depression (TRD) has been described elsewhere as failure to respond to adequate treatment by two different antidepressants. This definition is problematic as it suggests that TRD is a subtype of major depressive disorder (MDD), inferring a boundary between TRD and depression that is not treatment resistant. However, there is scant evidence to suggest that a discrete TRD entity exists as a distinct subtype of MDD, which itself is not a discrete or homogeneous entity. Similarly, the boundary between TRD and other forms of depression is predicated at least in part on regulatory and research requirements rather than biological evidence or clinical utility. AIM: This paper aims to investigate the notion of treatment failure in order to understand (i) what is TRD in the context of a broader formulation based on the understanding of depression, (ii) what factors make an individual patient difficult to treat, and (iii) what is the appropriate and individualised treatment strategy, predicated on an individual with refractory forms of depression? METHOD: Expert contributors to this paper were sought internationally by contacting representatives of key professional societies in the treatment of MDD - World Federation of Societies for Biological Psychiatry, Australasian Society for Bipolar and Depressive Disorders, International Society for Affective Disorders, Collegium Internationale Neuro-Psychopharmacologium and the Canadian Network for Mood and Anxiety Treatments. The manuscript was prepared through iterative editing. OUTCOMES: The concept of TRD as a discrete subtype of MDD, defined by failure to respond to pharmacotherapy, is not supported by evidence. Between 15 and 30% of depressive episodes fail to respond to adequate trials of 2 antidepressants, and 68% of individuals do not achieve remission from depression after a first-line course of antidepressant treatment. Failure to respond to antidepressant treatment, somatic therapies or psychotherapies may often reflect other factors including; biological resistance, diagnostic error, limitations of current therapies, psychosocial variables, a past history of exposure to childhood maltreatment or abuse, job satisfaction, personality disorders, co-morbid mental and physical disorders, substance use or non-adherence to treatment. Only a subset of patients not responding to antidepressant treatment can be explained through pharmacokinetic or pharmacodynamics mechanisms. We propose that non remitting MDD should be personalised, and propose a strategy of 'deconstructing depression'. By this approach, the clinician considers which factors contribute to making this individual both depressed and 'resistant' to previous therapeutic approaches. Clinical formulation is required to understand the nature of the depression. Many predictors of response are not biological, and reflect a confluence of biological, psychological, and sociocultural factors, which may influence the illness in a particular individual. After deconstructing depression at a personalised level, a personalised treatment plan can be constructed. The treatment plan needs to address the factors that have contributed to the individual's hard to treat depression. In addition, an individual with a history of illness may have a lot of accumulated life issues due to consequences of their illness, and these should be addressed in a recovery plan. LIMITATIONS: A 'deconstructing depression' qualitative rubric does not easily provide clear inclusion and exclusion criteria for researchers wanting to investigate TRD. CONCLUSIONS: MDD is a polymorphic disorder and many individuals who fail to respond to standard pharmacotherapy and are considered hard to treat. These patients are best served by personalised approaches that deconstruct the factors that have contributed to the patient's depression and implementing a treatment plan that adequately addresses these factors. The existence of TRD as a discrete and distinct subtype of MDD, defined by two treatment failures, is not supported by evidence.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hirschfeld, R. M. A., Williams, J. B. W., Spitzer, R. L., Calabrese, J. R., Flynn, L., Keck, P. E., Lewis, L., McElroy, S. L., Post, R. M., Rapport, D. J., et al. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.11.1873 · Cited by 1,525
Nanni, V., Uher, R., & Danese, A. (2012) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.11020335 · Cited by 1,480
Sheehan, D. V., Harnett-Sheehan, K., & Raj, B. A. (1996) · International Clinical Psychopharmacology · doi:10.1097/00004850-199606003-00015 · Cited by 1,440
Kennedy, S. H., Lam, R. W., McIntyre, R. S., Tourjman, S. V., Bhat, V., Blier, P., Hasnain, M., Jollant, F., Levitt, A. J., MacQueen, G. M., et al. (2016) · The Canadian Journal of Psychiatry · doi:10.1177/0706743716659417 · Cited by 1,181 · cited 1×
“…2013, 2015, 2017), Texas Medication Algorithm Project (TMAP) (Suehs et al. 2008), CANMAT guidelines (Kennedy et al. 2009; Lam, Kennedy, et al. 2009; Kennedy et al. 2016; Lam, Kennedy, et al. 2016; Lam, McIntosh, et al. 2016; MacQueen et al. 2016; Milev et al. 2016; Parikh et al. 2016; Ravindran et…”
Self-citationAssociation of socioeconomic position with health behaviors and mortality
Stringhini, S. (2010) · JAMA · doi:10.1001/jama.2010.297 · Cited by 1,065 · cited 2×
“…the WFSBP guidelines (Bauer et al. 2002a, 2002b; Bauer 2007; Bauer et al. 2007, 2013, 2015, 2017), Texas Medication Algorithm Project (TMAP) (Suehs et al. 2008), CANMAT guidelines (Kennedy et al. 2009; Lam, Kennedy, et al. 2009; Kennedy et al. 2016; Lam, Kennedy, et al. 2016; Lam, McIntosh,…”
Popova, V., Daly, E. J., Trivedi, M., Cooper, K., Lane, R., Lim, P., Mazzucco, C., Hough, D., Thase, M. E., Shelton, R. C., et al. (2019) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2019.19020172 · Cited by 904
Self-citationMalhi, G. S., Bassett, D., Boyce, P., Bryant, R., Fitzgerald, P. B., Fritz, K., Hopwood, M., Lyndon, B., Mulder, R., Murray, G., et al. (2015) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867415617657 · Cited by 842 · cited 3×
“…(Kennedy et al. 2009; Lam, Kennedy, et al. 2009; Kennedy et al. 2016; Lam, Kennedy, et al. 2016; Lam, McIntosh, et al. 2016; MacQueen et al. 2016; Milev et al. 2016; Parikh et al. 2016; Ravindran et al. 2016), RANZCP (Ellis 2004; Malhi et al. 2015) and NICE guidelines (NICE Guidance 2018).”
BackgroundSelf-citationMcIntyre, R. S., Cha, D. S., Soczynska, J. K., Woldeyohannes, H. O., Gallaugher, L. A., Kudlow, P., Alsuwaidan, M., & Baskaran, A. (2013) · Depression and Anxiety · doi:10.1002/da.22063 · Cited by 765
Self-citationBauer, M., Pfennig, A., Severus, E., Whybrow, P. C., Angst, J., Möller, H.-J., & Šon behalf of the Task Force on Unipolar Depressive Disorders (2013) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2013.804195 · Cited by 632
Self-citationMilev, R. V., Giacobbe, P., Kennedy, S. H., Blumberger, D. M., Daskalakis, Z. J., Downar, J., Modirrousta, M., Patry, S., Vila-Rodriguez, F., Lam, R. W., et al. (2016) · The Canadian Journal of Psychiatry · doi:10.1177/0706743716660033 · Cited by 586 · cited 1×
“…(Kennedy et al. 2009; Lam, Kennedy, et al. 2009; Kennedy et al. 2016; Lam, Kennedy, et al. 2016; Lam, McIntosh, et al. 2016; MacQueen et al. 2016; Milev et al. 2016; Parikh et al. 2016; Ravindran et al. 2016), RANZCP (Ellis 2004; Malhi et al. 2015) and NICE guidelines (NICE Guidance 2018).”
BackgroundSelf-citation
Cited by
Marx, W., Penninx, B. W. J. H., Solmi, M., Furukawa, T. A., Firth, J., Carvalho, A. F., & Berk, M. (2023) · Nature Reviews Disease Primers · doi:10.1038/s41572-023-00454-1 · Cited by 768
Self-citationMolecular Mechanisms of Psilocybin and Implications for the Treatment of Depression
Ling, S., Ceban, F., Lui, L. M. W., Lee, Y., Teopiz, K. M., Rodrigues, N. B., Lipsitz, O., Gill, H., Subramaniapillai, M., Mansur, R. B., et al. (2022) · CNS Drugs · doi:10.1007/s40263-021-00877-y · Cited by 127
Self-citationMcIntyre, R. S., Lipsitz, O., Lui, L. M. W., Rodrigues, N. B., Gill, H., Nasri, F., Ling, R., Teopiz, K. M., Ho, R. C., Subramaniapillai, M., et al. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2021.07.035 · Cited by 21
Self-citationTripi, D., Giantesani, M., Arena, J. F., & Ferracuti, S. (2026) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2026.1835123
Metadata
- Authors
- Dodd, S., Bauer, M., Carvalho, A. F., Eyre, H., Fava, M., Kasper, S., Kennedy, S. H., Khoo, J.-P., Lopez Jaramillo, C., Malhi, G. S., McIntyre, R. S., Mitchell, P. B., Castro, A. M. P., Ratheesh, A., Severus, E., Suppes, T., Trivedi, M. H., Thase, M. E., Yatham, L. N., Young, A. H., & Berk, M.
- Venue
- The World Journal of Biological Psychiatry
- Publisher
- Informa UK Limited
- Published
- 2020-12-08
- Volume
- 22
- Issue
- 7
- Pages
- 483-494
- ISSN
- 1562-2975 (ISSN-L)
- 1814-1412
- OpenAlex
- W3112171960
- Cited by
- 88
- References
- 35
- FWCI
- 3.77
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A clinical approach to treatment resistance in depressed patients: What to do when the usual treatments don’t work well enough? https://app.cochat.ai/papers/10.1080/15622975.2020.1851052
- The paper
- Dodd, S., Bauer, M., Carvalho, A. F., Eyre, H., Fava, M., Kasper, S., Kennedy, S. H., Khoo, J.-P., Lopez Jaramillo, C., Malhi, G. S., McIntyre, R. S., Mitchell, P. B., Castro, A. M. P., Ratheesh, A., Severus, E., Suppes, T., Trivedi, M. H., Thase, M. E., Yatham, L. N., . . . Berk, M. (2021). A clinical approach to treatment resistance in depressed patients: What to do when the usual treatments don’t work well enough? The World Journal of Biological Psychiatry. https://doi.org/10.1080/15622975.2020.1851052
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.